
    
      The investigational drug in this protocol is bavituximab, which will be delivered
      concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks
      of bavituximab administration by itself. If the other therapies are terminated after week 4
      the bavituximab treatment may be continued per protocol. A chemotherapy agent, capecitabine,
      will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825
      mg/m2. Radiation therapy will be administered daily, Monday-Friday, for a total of 28
      treatments, delivered at 1.8 Gy/fraction. Surgery will follow the last bavituximab
      administration by 4-8 weeks (6-10 weeks following completion of radiation therapy.
    
  